# NCT06074588 (NCT06074588)

> Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

No report yet. It can be ordered.

- Drugs tested: sacituzumab tirumotecan
- Indication: previously treated advanced nonsquamous NSCLC with genomic alterations

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06074588
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Non-small Cell Lung Cancer (NSCLC)
- Interventions: Sacituzumab tirumotecan; Docetaxel; Pemetrexed
- Enrollment: 556
- Primary outcome: Overall Survival (OS) of Participants with NSCLC with Epidermal Growth Factor Receptor (EGFR) Mutations

## Indexed commentary on NCT06074588 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct06074588
